IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Antidiabetic Properties of Rose Hip
This study has been completed.
Sponsor:
Lund University
Information provided by:
Lund University
ClinicalTrials.gov Identifier:
NCT01316016
First received: March 15, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether daily intake of a drink containing rose hip powder reduces risk markers of type diabetes and cardiovascular disease.
| Condition | Intervention |
|---|---|
| Obesity | Dietary Supplement: Rose hip |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment |
| Official Title: | Effects of Rose Hip Intake on Risk Markers of Type 2 Diabetes and Cardiovascular Disease: a Randomized Double-blind Cross-over Investigation in Obese Persons |
Further study details as provided by Lund University:
| Enrollment: | 31 |
| Study Start Date: | April 2009 |
| Study Completion Date: | January 2011 |
| Primary Completion Date: | February 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Rose hip |
Dietary Supplement: Rose hip
40 g of rose hip powder daily for 6 weeks.
|
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- BMI > 30
- willingness to participate in the study
- willingness to comply with the daily intake of drinks and the recommended energy intake during the course of the study
Exclusion Criteria:
- diabetes
- previous or ongoing insulin treatment
- abnormal thyroid status
- abnormal liver status
- abnormal kidney status
- known gastrointestinal disorder
- pregnancy
- suspected allergy to ingredients of the drinks
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01316016
Please refer to this study by its ClinicalTrials.gov identifier: NCT01316016
Locations
| Sweden | |
| Endocrinology Clinic, Lund University Hospital | |
| Lund, Sweden, SE-22185 | |
Sponsors and Collaborators
Lund University
Investigators
| Study Chair: | Per Katzman, MD/PhD | Lund University |
More Information
Additional Information:
Publications:
| Responsible Party: | Cecilia Holm, Lund University |
| ClinicalTrials.gov Identifier: | NCT01316016 History of Changes |
| Other Study ID Numbers: |
LUAFC002 |
| Study First Received: | March 15, 2011 |
| Last Updated: | March 15, 2011 |
Keywords provided by Lund University:
|
obesity glucose intolerance cholesterol blood pressure |
ClinicalTrials.gov processed this record on August 18, 2017